---
schema_version: "secwatch.filing_event.v1"
accession: "0001999480-26-000022"
form_type: "8-K"
ticker: "ANRO"
cik: "0001999480"
company_name: "Alto Neuroscience, Inc."
filed_at: "2026-08-12T20:14:32+00:00"
generated_at: "2026-08-12T20:15:12.114521+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Alto Neuroscience Q2 net loss $27.6M; expands ALTO-207 with Phase 3 monotherapy trial

## Summary
- Net loss $27.6M in Q2 2026 vs $17.7M year-ago; R&D expenses $22.1M vs $13.1M.
- July 2026 offering raised ~$100M gross; pro forma cash ~$338M, runway through 2030.
- ALTO-207 Phase 3 monotherapy TRD trial added; PACE-2 Phase 3 adjunctive to start early 2027; PACE-1 Phase 2b topline 2H 2027.
- Nature Medicine PRIME-PRAXOL: pramipexole reduced anhedonia (SHAPS p=0.006, Hedges' g=0.62) in MDD/bipolar depression.
- ALTO-300 Phase 2b MDD topline 1H 2027; ALTO-100 Phase 2b BPD topline mid-2027.

## SEC filing metadata
- accession: 0001999480-26-000022
- form_type: 8-K
- ticker: ANRO
- cik: 0001999480
- company_name: Alto Neuroscience, Inc.
- filed_at: 2026-08-12T20:14:32+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1999480/000199948026000022/0001999480-26-000022-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1999480/000199948026000022/alto-20260812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001999480-26-000022
- JSON: https://secwatch.observer/filing/0001999480-26-000022.json
- Plain text: https://secwatch.observer/filing/0001999480-26-000022.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.